GSK5764227

BIOLOGICAL6 trials

Sponsors

GlaxoSmithKline, University Health Network, Toronto

Conditions

Gastrointestinal NeoplasmsNeoplasmsNeoplasms, LungRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active, not recruitingNCT05277051

GlaxoSmithKlineNeoplasms

Start: 2022-03-22End: 2027-08-31Updated: 2026-03-23

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

RecruitingNCT06551142

GlaxoSmithKlineNeoplasms

Start: 2024-09-30End: 2027-05-19Target: 590Updated: 2025-12-18

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

RecruitingNCT06885034

GlaxoSmithKlineGastrointestinal Neoplasms

Start: 2025-06-11End: 2028-06-23Target: 320Updated: 2025-11-18

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

RecruitingNCT07277270

GlaxoSmithKlineNeoplasms

Start: 2025-12-03End: 2028-09-29Target: 84Updated: 2026-01-07

Phase 2

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruitingNCT07408063

University Health Network, TorontoRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2026-02-02End: 2030-06-30Target: 30Updated: 2026-02-12

Phase 3

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

RecruitingNCT07099898

GlaxoSmithKlineNeoplasms, Lung

Start: 2025-08-11End: 2029-09-28Target: 420Updated: 2026-03-06

Related Papers

A phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 (GSK’227), alone and in combination in patients with previously treated advanced unresectable or metastatic gastrointestinal solid tumors.

Journal of Clinical Oncology2026-01-10

Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors

Cancer Research2025-04-25

A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.

Journal of Clinical Oncology2025-01-273 citations